Our Mission
RenalGuard Solutions, Inc. is a medical device company focused on innovative technologies for the cardiac and vascular markets. The company’s lead product is designed to protect patients from procedure-induced acute kidney injury (AKI) which may result from cardiac surgery and heart cath procedures, and may also be present in ICU patients. Our goal is to help improve morbidity and mortality rates in these patients, preserve quality of life, and reduce healthcare costs through the use of our technology.
Board of Directors
Ethan Benovitz
Chairman
Ilya Budik
Director
Shawn Langer, MD
Director
Alan Adler, MBA
Director
Intellectual Property
Clinical Investigations
| Trial | Principal Investigator | Objective | Summary |
|---|---|---|---|
| KIDNEY | Heyman Luckraz, MD | Assess the impact of the RenalGuard(r) system on the reduction of AKI in patients undergoing cardiac surgery | In patients at-risk for AKI, undergoing cardiac surgery with the cardiac pulmonary bypass, the RenalGuard system significantly reduced the incidence of AKI. The RenalGuard system can be used safely and reproducibly in Cardiac Surgery. |
| REMEDIAL III | Carlo Briguori, MD | Evaluate the ability of the two most successful patient “tailored hydration regimens” to protect at-risk patients from CI-AKI by comparing RenalGuard Therapy with left ventricular end-diastolic pressure (LVEDP)-guided hydration (the “POSEIDON” method). | The investigators concluded that RenalGuard Therapy is superior to the LVEDP-guided hydration regimen to prevent the composite of CI-AKI and/or acute pulmonary edema in high-risk patients. |
| PROTECT-TAVI | Marco Barbanti, MD | Investigate the effect of the RenalGuard System on prevention of acute kidney injury (AKI) in patients undergoing transcatheter aortic valve replacement (TAVR). | Furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard system is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVR. |
| AKIGuard | Tullio Usmiani, MD | Compare sodium bicarbonate/isotonic saline/N-acetylcysteine/vitamin C prophylaxis (BS-NAC) against high-volume forced diuresis with matched hydration in CI-AKI prevention in patients with chronic kidney disease undergoing coronary angiography or percutaneous coronary intervention. | Demonstrated significant improvement in long-term outcomes when using RenalGuard vs. standard therapy. |
| MYTHOS | Antonio Bartorelli, MD Giancarlo Marenzi, MD |
Compare the rates of CIN in at-risk patient who receive induced diuresis with automated matched hydration therapy utilizing RenalGuard, compared to patients who receive standard overnight hydration. | Patients who were at higher risk for renal failure and who were treated with RenalGuard while undergoing imaging procedures developed CIN at a rate 74% lower than those who were treated with overnight hydration. |
| REMEDIAL II | Carlo Briguori, MD | Study the efficacy of RenalGuard Therapy compared to the current standard of care. | RenalGuard Therapy is superior to sodium bicarbonate and N-acetylcysteine in preventing contrast-induced acute kidney injury in high-risk patients. |
Clinical Articles
The following papers and abstracts discuss the use of RenalGuard Therapy in the prevention of Contrast-Associated AKI (CA-AKI).
RenalGuard – Designed to Prevent AKI
RenalGuard and TAVI procedures
RenalGuard Interviews
Certifications
RenalGuard Solutions, Inc. is focused on meeting our customers’ requirements by delivering high quality products in compliance with all applicable standards.
Download our certifications below:
Peristaltic Infusion Pump Controller and Sterile Administration Sets CE Certificate